ストックスクリーナーアプリを入手
36.35
6.96%
-2.72
プレマーケット:
36.25
-0.10
-0.28%
Moonlake Immunotherapeutics (MLTX) 最新ニュース
How the (MLTX) price action is used to our Advantage - news.stocktradersdaily.com
MoonLake’s 37% decline validates InvestingPro’s overvaluation warning By Investing.com - Investing.com Australia
Long Term Trading Analysis for (MLTX) - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Bought by PNC Financial Services Group Inc. - Defense World
BTIG maintains Moonlake stock Buy rating and $81 target By Investing.com - Investing.com Australia
MoonLake Immunotherapeutics’ Sonelokimab Positioned as Leading Treatment for Hidradenitis Suppurativa Amidst Weak JAK Inhibitor Competition - TipRanks
BTIG maintains Moonlake stock Buy rating and $81 target - Investing.com
MoonLake Immunotherapeutics (NASDAQ:MLTX) Coverage Initiated by Analysts at Royal Bank of Canada - Defense World
MoonLake earns new Outperform at RBC Capital Markets on lead drug - MSN
RBC Capital Initiates Coverage of MoonLake Immunotherapeutics (MLTX) with Outperform Recommendation - Nasdaq
MoonLake stock earns new Outperform at RBC (MLTX:NASDAQ) - Seeking Alpha
Why MoonLake Immunotherapeutics Shares Are Rising - TipRanks
Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? - MSN
Guggenheim maintains $80 target on Moonlake Immunotherapeutics stock - Investing.com
MoonLake Immunotherapeutics initiated with an Outperform at RBC Capital - TipRanks
Correction: RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $67 Price Target - MarketScreener
RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $17 Price Target - Marketscreener.com
MoonLake Immunotherapeutics: Advancing Sonelokimab with Promising Phase III VELA Program and Favorable Market Positioning - TipRanks
MoonLake Immunotherapeutics Advances Clinical Trials in 2024 - TipRanks
MoonLake’s CEO on its looming mid-year pivotal readout in skin disease - Endpoints News
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by Victory Capital Management Inc. - Defense World
Cowen maintains Buy on Moonlake Immunotherapeutics stock By Investing.com - Investing.com Australia
Cowen maintains Buy on Moonlake Immunotherapeutics stock - Investing.com India
MoonLake Immunotherapeutics: Promising Prospects for Sonelokimab in Inflammatory Diseases - TipRanks
Why MoonLake Immunotherapeutics is the Dark Horse Pharma Stock to Watch in 2025 - DSA
Optimistic Outlook for MoonLake Immunotherapeutics: Promising Developments and Market Opportunities for Sonelokimab - TipRanks
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
The Goldman Sachs Group Cuts MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $73.00 - Defense World
Brokers Offer Predictions for MLTX Q2 Earnings - MarketBeat
MoonLake Immunotherapeutics (MLTX) Projected to Post Earnings on Thursday - MarketBeat
(MLTX) Technical Pivots with Risk Controls - Stock Traders Daily
The Goldman Sachs Group Has Lowered Expectations for MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price - MarketBeat
MoonLake Immunotherapeutics' (MLTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Needham & Company LLC Increases MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $66.00 - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Issues Earnings Results, Misses Expectations By $0.09 EPS - MarketBeat
MoonLake Immunotherapeutics: Buy Rating Backed by Promising SLK Data and Strong Financial Position - TipRanks
MoonLake Immunotherapeutics (MLTX) to Release Quarterly Earnings on Thursday - Defense World
Buy Rating for MoonLake Immunotherapeutics Driven by Promising Clinical Programs and Market Potential - TipRanks
Moonlake Immunotherapeutics Faces Hurdles in Commercializing SLK Despite Potential Approvals - TipRanks
MoonLake Immunotherapeutics: Strong Buy Rating Amid Promising Phase 3 Trials and Robust Financial Position - TipRanks
Buy Rating for MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Developments - TipRanks
MoonLake Immunotherapeutics: Promising Future with Strong Financial Position and Clinical Advancements - TipRanks
MoonLake Immunotherapeutics reports Q4 EPS (72c), consensus (59c) - TipRanks
MoonLake Immunotherapeutics Q4 Loss Widens -February 26, 2025 at 07:53 am EST - Marketscreener.com
Earnings Flash (MLTX) MoonLake Immunotherapeutics Posts Q4 Loss of $-0.72 a Share, vs. FactSet Est of $-0.59 Loss - Marketscreener.com
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - The Manila Times
MoonLake Immunotherapeutics SEC 10-K Report - TradingView
Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now? - Insider Monkey
This MoonLake Immunotherapeutics Insider Reduced Their Stake By 50% - simplywall.st
3.89%
0.13%
大文字化:
|
ボリューム (24 時間):